Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.53 |
| ▸ | HRH2 | P25021 | 4/20 | 0.48 |
| ▸ | HRH1 | P35367 | 4/20 | 0.48 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | JAK1 | P23458 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21584005 | 1.00 | CTSK (0.53) | CTSKHRH2HRH1KCNA3CA1 | |
| SCHEMBL1700415 | 0.92 | CTSK (0.56) | CTSKHRH2HRH1KCNA3CA1 | |
| SCHEMBL1700413 | 0.92 | CTSK (0.56) | CTSKHRH2HRH1KCNA3CA1 | |
| SCHEMBL24690239 | 0.92 | KCNA3 (0.54) | CTSKHRH2HRH1KCNA3CA1 | |
| SCHEMBL1810659 | 0.92 | CTSK (0.56) | CTSKHRH2HRH1KCNA3CA1 | |
| SCHEMBL24098366 | 0.91 | CA1 (0.49) | CTSKHRH2HRH1KCNA3CA1 | |
| SCHEMBL20089656 | 0.89 | CTSK (0.45) | CTSKHRH2HRH1KCNA3CA1 | |
| SCHEMBL13583443 | 0.88 | CTSK (0.54) | CTSKHRH2HRH1KCNA3CA1 | |
| SCHEMBL13583442 | 0.88 | CTSK (0.54) | CTSKHRH2HRH1KCNA3CA1 | |
| SCHEMBL25700736 | 0.87 | CTSK (0.51) | CTSKHRH2HRH1KCNA3CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570652-B2 | Pyrrolidine compound and use thereof | SIMCERE PHARMACEUTICAL CO., LTD. (CN) | 2026-03-10 | — | — | US | disclosed |
| US-20240208932-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240208932-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240208932-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| EP-4371977-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2024-05-22 | — | — | EP | disclosed |
| WO-2024042185-A1 | NOVEL SUBSTITUTED TETRAHYDROISOQUINOLINE-6- CARBOXYLIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF. | SANOFI (FR) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024042163-A1 | NOVEL SUBSTITUTED 2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B]INDOLE CARBOXYLIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2024-02-29 | — | — | WO | disclosed |
| US-20230348459-A1 | PYRROLIDINE COMPOUND AND USE THEREOF | SIMCERE PHARMACEUTICAL CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348459-A1 | PYRROLIDINE COMPOUND AND USE THEREOF | SIMCERE PHARMACEUTICAL CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| CN-116964049-A | Estrogen receptor modulators | 里科瑞尔姆IP控股有限责任公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-116731064-A | Tricyclic tetrahydroisoquinoline derivative, preparation method and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-114746424-B | Tricyclic tetrahydroisoquinoline derivative, preparation method and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2023-06-16 | — | — | CN | disclosed |
| EP-4151636-A1 | PYRROLIDINE COMPOUND AND USE THEREOF | Simcere Pharmaceutical Co. Ltd. (CN) | 2023-03-22 | — | — | EP | disclosed |
| WO-2023284837-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | 四川海思科制药有限公司 | 2023-01-19 | — | — | WO | disclosed |
| CN-115611895-A | Arylamino derivative estrogen receptor modulators and uses thereof | 四川海思科制药有限公司 | 2023-01-17 | — | — | CN | disclosed |
| CN-114746424-A | Tricyclic tetrahydro isoquinoline derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-07-12 | — | — | CN | disclosed |
| WO-2021228210-A1 | PYRROLIDINE COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208932-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | GPER1, ESR1, ESRRA | CTSK 3927/4885HRH2 682/4885HRH1 807/4885 |
| US-12570652-B2 | Pyrrolidine compound and use thereof | ESR1, PGR, ESR2 | CTSK 1426/4885HRH2 1099/4885HRH1 1000/4885 |
| US-20230348459-A1 | PYRROLIDINE COMPOUND AND USE THEREOF | ESR1, PGR, GPER1 | CTSK 1335/4885HRH2 1511/4885HRH1 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.